|
Totally high-risk patient populations
|
8
|
5.85 (3.69, 9.26); I2 = 19.8%
|
|
Low risk of bias
|
6
|
5.07 (3.38, 7.59); I2 = 0.0%
|
|
CS infection comparator
|
5
|
5.24 (2.65, 10.37); I2 = 32.1%
|
|
No CR infection comparator
|
3
|
7.02 (3.33, 14.80); I2 = 18.4%
|
|
No infection comparator
|
2
|
24.76 (4.14, 148.00); I2 = 71.4%
|
|
In-hospital/≤30-day mortality
|
4
|
6.08 (3.83, 9.66); I2 = 0.0%
|
|
Longer-term (> 30 days) mortality
|
5
|
6.56 (2.81, 15.33); I2 = 51.3%
|
|
Italy
|
3
|
5.86 (3.65, 9.41); I2 = 0.0%
|
|
USA
|
5
|
5.40 (2.58, 11.30); I2 = 34.1%
|
|
Partially and totally high-risk patient populations
|
14
|
4.13 (2.70, 6.31); I2 = 71.5%
|
|
Low risk of bias
|
9
|
3.94 (2.32, 6.68); I2 = 71.4%
|
|
CS infection comparator
|
10
|
3.39 (2.11, 5.45); I2 = 70.2%
|
|
No CR infection comparator
|
3
|
7.02 (3.33, 14.80); I2 = 18.4%
|
|
No infection comparator
|
3
|
13.39 (4.09, 43.87); I2 = 75.0%
|
|
In-hospital/≤30-day mortality
|
10
|
3.74 (2.37, 5.89); I2 = 74.2%
|
|
Longer-term (> 30 days) mortality
|
5
|
6.56 (2.81, 15.33); I2 = 51.3%
|
|
CRKP studies only
|
12
|
4.68 (3.03, 7.23); I2 = 61.0%
|
|
CRPA studies only
|
2
|
2.25 (0.84, 6.03); I2 = 77.6%
|
|
Italy
|
5
|
4.21 (2.17, 8.14); I2 = 73.3%
|
|
USA
|
9
|
3.83 (2.54, 5.76); I2 = 28.1%
|
